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ABSTRACT
The purpose of this investigation was to determine if ten weeks of aerobic exercise training
could increase hepatic glycogen storage in rats with Type 1 Diabetes Mellitus (T1DM) and whether
elevated hepatic glycogen content is associated with alterations in glycogenic proteins and insulin
signaling. Rats were divided into control-sedentary, control-exercised, T1DM-sedentary and T1DMexercised groups. Animals from each group underwent a euglycemic-hyperinsulinemic clamp at the
conclusion of the study. Exercise training consisted of treadmill running at 27m/min, 6% incline for
1hr, five days/week for ten weeks. T1DM rats had lower liver glycogen concentrations than control
rats and glycogen was not increased with training. GS, GK and PEPCK protein contents were also
increased in the T1DM groups. Insulin-clamp stimulated GSK phosphorylation was not different
between treatments. These findings indicate that aerobic exercise training does not increase liver
glycogen content in T1DM rats despite increases in glycogenic protein content and normal insulin
signaling.
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CHAPTER 1
1.1 Introduction
Type 1 diabetes mellitus (T1DM) is a disease associated with the autoimmune-mediated
destruction of the insulin secreting cells of the endocrine pancreas, the islet β cells, which
prevents the natural secretion of insulin in response to elevated blood glucose levels. As the
primary role of insulin is to initiate glucose uptake in peripheral tissues, patients suffer from
chronic hyperglycemia. This deficit in glucose metabolism manifests a host of diabetes-related
complications including cardiovascular disease, neuropathy, nephropathy, retinopathy and insulin
resistance 1,2. Furthermore, these complications worsen as the patient progresses through life,
such that the life expectancy of a patient with T1DM is dramatically reduced from 4 to 19 years
depending on age at diagnosis and treatment 3,4. Similar to the prevalence of type 2 diabetes
mellitus (T2DM), epidemiological data suggests that T1DM onset is increasing worldwide and in
both low (low incidence of disease) and high (high incidence of disease) risk populations 5.
To lower the risk of complications, T1DM patients are required to consistently monitor
blood glucose levels and adjust synthetic insulin injections to maintain their blood glucose to near
normalized levels. This modernized insulin therapy regime consists of multiple daily injections
(referred to as intensive insulin therapy), which is in stark contrast to more conventional insulin
therapy regimes that typically consist of a daily single dose of insulin 1,6. The Diabetes Control
and Complications Trial, a large multi-center and long term study of T1DM pathology, found that
this intensive insulin therapy produced lower blood glucose and glycosylated hemoglobin
(HBA1C) over time 1. These changes were in concert with reductions in both retinopathy and
neuropathy and improved the low-density lipoprotein profile of patients (an indicator for
cardiovascular disease risk) 1. This type of insulin treatment strategy is not without its
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challenges, including the incidence of severe hypoglycemia onset being increased 3-fold by
intensive treatment versus more conventional insulin therapy 1,6.
In addition to insulin supplementation, regular exercise is often advised as it has been
shown to help counteract many of the complications associated with T1DM. For example,
regular exercise has been shown to lower blood glucose concentrations and triglycerides, improve
bone health, decrease cardiovascular risk and increase insulin sensitivity, as well as increase lean
muscle and bone mass and decrease fat mass 7–9. Additionally, improved quality of life and sense
of well-being have also been reported in patients with T1DM following an exercise intervention
10

. Despite these known benefits, many patients with T1DM refrain from regular exercise due to

fear of experiencing severe hypoglycemia 10,11. The combination of insulin therapy and regular
exercise has been shown to improve health markers, but potentiate the risk of hypoglycemia onset
due to the potentiating effects of both factors on glucose uptake 12. As such, patients with T1DM
struggle to find a delicate and individualized balance between the dosage of insulin and the
amount of exercise required to achieve the health benefits associated with exercise and avoid
hypoglycemic episodes.
Patients with T1DM suffer from significant deficits in glucose metabolism, including
uptake, storage and release 13–17. Following exercise in both healthy and diabetic, glucose uptake
into peripheral tissues such as skeletal muscle increases dramatically and glucose production,
from hepatic stores or simple ingestion, must increase accordingly. However, hepatic glycogen
stores are known to be decreased in T1DM, impairing the liver’s ability to naturally release
glucose 17,18. Decreased production, combined with increased glucose use and improved insulin
sensitivity following exercise make it extremely difficult to maintain glucose homeostasis,
leading the T1DM patient to a severe risk of hypoglycemia onset 8. The mechanisms underlying
lowered levels of hepatic glycogen are not well understood; understanding these mechanisms may
provide insight into how we can mitigate post exercise hypoglycemia in T1DM.

3
1.2

Liver Physiology
The liver is a complex organ which is involved in several processes essential for survival.

Located in the upper right section of the abdominal cavity, the liver can be structurally divided
into four lobes, the left, right, caudate and quadrate lobes (located under the left and right lobes
respectively). The liver tissues consist of two primary cell types, parenchymal cells known as
hepatocytes, and non-parenchymal cells including sinusoidal epithelial cells, kupfer cells and
stellate cells. The blood supply to the liver comes from two sources, the hepatic artery which
supplies oxygenated blood directly from the aorta and the hepatic portal vein which brings
deoxygenated blood from the gastrointestinal tract, as well as the spleen and other organs 19. The
liver is able to obtain about half of its required oxygen from the portal vein, while the other half
comes from the hepatic artery 19. Arterial and venous blood mixes within hepatic sinusoids prior
to entering the hepatic vein for transport out of the liver. Functionally, the liver can be
subdivided into small clusters, or acini, which consist of a central arteriole surrounded by a group
of hepatocytes, which, in turn, are surrounded by venules which carry blood away from the liver
towards the vena cava 19. This arrangement creates a strong oxygen gradient (highest centrally,
decreasing distally), resulting in additional gradients in the activities of various enzymes. For
example, citric acid cycle and electron transport enzyme activities are highest centrally within
each acinus, where there is an abundance of oxygen, whereas glycolytic, non-oxygen requiring
enzymes, are higher in the periphery 19
The liver is highly innervated with both afferent and efferent sympathetic (SNS),
parasympathetic (PNS) and sensory neurons, allowing constant communication between the liver
and the brain 19. Afferent fibers are able to communicate directly with the central nervous
system, relaying information on blood temperature and pressure, as well as ion and nutrient
content (carbohydrate, lipids, proteins, and circulation hormones and growth factor levels)

20-21

.

Efferent nervous fibres allow central control over a multitude of functions for which the liver is
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responsible. Specifically applicable, the SNS is known to decrease liver glycogen content
through adrenergic-mediated release of glucose22. SNS denervation has also been shown to
decrease the rate of fatty acid oxidation via carnitine-palmitoyltransferase, which increases
circulating triglycerides and very low density lipoporteins (VLDL) as well as decreasing the
production of ketone bodies 23–25. Conversely, stimulation of the PNS has been shown to increase
rates of hepatic glycogen synthesis and increase production of a hepatic insulin sensitizing
substance (HISS), a yet unidentified molecule known to increase glucose uptake in skeletal
muscle 26–28. In addition to these metabolic influences, the SNS is known to decrease blood flow
to the liver via the hepatic artery without changing the overall distribution of blood within the
liver while the PNS has little impact 19.

1.2.1

Liver Functions
Liver functions can be divided into three main categories: nutrient processing,

biosynthesis and protection/filtering.
Nutrient Processing:
As the portal vein brings blood directly from the gastrointestinal tract to the liver, it is
exposed to all the nutrients absorbed following meal ingestion. One of the fundamental roles of
the liver is to maintain a normalized blood glucose concentration (~4 mM) 29. Carbohydrates,
primarily glucose and fructose, are taken up into hepatocytes where they have several potential
fates: direct metabolism into usable energy for the liver itself, storage as glycogen, or entered into
the pentose phosphate cycle and converted either into NADPH or ribose-5 phosphate 30. Meals
containing excess amounts of carbohydrate stimulate lipogenesis resulting in their conversion to
both glycerol and fatty acids for storage30. The liver also functions in de novo glucose production
via gluconeogenesis 29,30. This process uses non-carbohydrate precursors such as lactate and
certain amino acids to generate glucose 30. This is done by reversing, with a few additional
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enzymatic reactions, the process of glycolysis. During states of nutrient deprivation such as
fasting or in various disease states such as diabetes where glucose homeostasis is disrupted, this
process is critical to maintaining circulating blood glucose levels.
Fatty acids are also absorbed directly from the diet and are metabolized into usable
energy for the hepatocytes themselves, or, can be packaged for export 31. Individual fatty acids
combine to form triglycerides which are subsequently organized into lipoproteins (be it high, low
or very low density (HDL, LDL, VLDL, respectively)) for export or stored in hepatic vesicles for
future use 32. During periods of carbohydrate shortage, use of fatty acids increases greatly and as
a result, the production of ketone bodies, acetone, acetoacetate and 3-hydroxybutyrate, increase as
well 33. The liver is also responsible for the processing of cholesterol, necessary for the
production of many important molecules (steroid hormones including cortisol, testosterone and
estradiol, lipoproteins, as well as critical components in all cellular membranes). Cholesterol
molecules can be used within hepatocytes for the production of bile acids or packaged into
lipoproteins for export to peripheral tissues.
The liver also processes excess amino acids, resulting from either dietary sources or
normal protein turnover. These amino acids are degraded in the urea cycle for excretion. Nonessential amino acids can also be synthesized within the liver, provided the necessary essential
amino acids are present 34. Finally, the liver is also a site for the storage of excess vitamins and
minerals including vitamins A, D, B12, K and iron 35–38.
Biosynthesis:
A second important function of the liver is the biosynthesis of compounds necessary for
normal body function. In addition to glucose, fat and amino acid synthesis, albumin, a major
component of blood plasma, is produced in the liver and binds proteins, fats, hormones and many
other constituents, within the blood to maintain the osmotic pressure39. Coagulation factors such
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as fibrinogen and prothrombin are also synthesized in the liver, as well as binding proteins,
apoferritin and transferrin, which are important for the transport of iron in the blood 40,41.
Furthermore, bile salts, compounds necessary for the digestion and absorption of fats from the
digestive tract, are also produced and secreted from the liver 42.
Protection:
The last major function of the liver is protection and clearance of potentially harmful
substances from the body. The gastrointestinal tract, particularly the colon, contains bacteria
which is a potential risk to enter circulation. Kupfer cells within the hepatic sinusoids are potent
macrophages which scavenge and can clear bacterium from hepatic sinusoids 19. Similarly, the
liver is able to clear toxins, hormones, and other harmful substances from the blood through
oxidative reactions that disrupt foreign substances without damaging its own proteins and DNA
34,43

. For instance, the liver is heavily involved in the clearance of hormones such as insulin and

glucagon and plays an important role in the metabolism of the drugs used to treat any number of
conditions 34.

1.3

Glycogen Metabolism
There are two primary stores of carbohydrate in the body, liver and muscle glycogen.

While small amounts have been shown to exist in other areas (neurons, the brain etc.) these
quantities make up a very small proportion of total energy storage 44. Glycogen is a branched
polymer of glucose residues and functions to release glucose into circulation when it is
unavailable from the diet (i.e. during fasting) 44. Muscle glycogen is stored mainly for fueling
muscle contraction, while liver glycogen stores serve to maintain blood glucose homeostasis 44–46.
Glucose release from the liver is critical in times of increased glucose uptake into peripheral
tissues, such as skeletal muscle, during exercise 45,46. The maintenance of normalized
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concentrations of glucose in the blood is critical for organs such as the brain which rely heavily
on a steady flow of glucose in the blood to function 34,44.
Glycogen synthesis (shown in figure 1.1) is initiated by a single protein, glycogenin,
which is able to self-glycosylate, creating an eight residue chain 47. This glucosyl chain, in turn,
is extended by forming alpha-1,4 glycosidic bonds to the existing end of the chain 47. Once
thirteen residues are linked linearly, a branch is then created by removing the final four residues
and reattaching them via an alpha-1,6 linkage 44,47. Each thirteen-residue chain will have two
alpha-1,6 branch points, creating a densely packed granule. Successive “tiers” are created in this
fashion until the upper limit of twelve tiers, has been reached 44. A full twelve-tier glycogen
molecule would contain approximately fifty-five thousand residues; although, analysis of particle
size suggests the average is closer to seven tiers 46. The glycogen granule is not solely composed
of carbohydrate. Known as a glycosome, many proteins involved in the synthesis and
degradation of glycogen, as well as an abundance of downstream regulators, also participate in
binding to the granule 48. While the specific function is unknown, it is believed the function of
the glycosome is to provide a scaffold to bring many of the necessary enzymes into close
association with each other to allow coordinated and timely control of glycogen metabolism 44,48.
The glycogen concentration is controlled by the relative activities of two enzymes,
glycogen synthase (GS) and glycogen phosphorylase (GP). The synthesis of glycogen is mediated
by GS which functions to add glucose units to a glycogen chain, while GP is responsible for the
breakdown of the glycogen molecule through the removal of glucose units

44

. GS is expressed in

two isoforms, a liver-specific form and a more widely expressed, muscle isoform 44,49,50 and can
synthesize glycogen through a direct or indirect pathway 44,51. The direct pathway involves the
uptake of glucose into either the liver or skeletal muscle and its subsequent phosphorylation into
glucose-6-phosphate (G6P) 44,52. G6P is then converted into glucose-1-phosphate (G1P), which is
subsequently converted to uridine diphosphate-glucose (UDPG) by UDP-glucose-
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pyrophosphorylase. UDPG molecules are assembled into a glycogen chain by GS, adding
residues by the formation of α1-4 bonds, while an additional enzyme, the branching enzyme,
removes existing 1-4 bonds and creates the α1-6 branch points. The indirect pathway exists
primarily in the liver, but can also occur in the kidneys, involving the gluconeogenic creation of
G6P from three-carbon precursors including lactate, glycerol and alanine 51,53. This pathway is
less efficient than direct synthesis but allows glycogen to be synthesized from non-carbohydrate
sources 51,53.

9

Figure 1.1 Steps in Glycogen Synthesis.
Abbreviations: UDP, uridine diphosphate; UDPG, uridine diphosphate-glucose; UDPGPP UDPGpyrophosphorylase; PGM, phsphoglucomutase; GK, glucokinase; PEPCK, phosphoenolpyruvate
carboxykinase; Lac, lactate, Pyr, pyruvate; Ala, alanine

Adapted from:
Bollen, M., Keppens, S. & Stalmans, W. Specific features of glycogen metabolism in the liver.
Biochem J 336, 19–31 (1998).
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1.4

Glucose Processing
Glucose uptake into the liver is mainly accomplished through the glucose transporter 2

(GLUT2) protein 54. Although GLUT2 is located in several tissues, the highest levels of this
protein are expressed in the liver hepatocytes and pancreatic β-cells 54,55. It is constitutive to the
membrane and allows glucose uptake via facilitated, yet passive, transport. Although GLUT2 has
a high capacity for glucose uptake, the affinity for the glucose molecule is low by comparison to
other GLUT isoforms 54,56,57. This low affinity for glucose is favourable during conditions of
lowered blood glucose concentrations, preventing excessive glucose uptake and subsequent
hypoglycemia onset. Glucose uptake and subsequent metabolism is critical in the β-cells
mechanism for insulin secretion, reinforcing the importance of a selective transporter 55,58.
Upon entering the hepatocyte, glucose is phosphorylated into G6P by a liver-specific
hexokinase, glucokinase (GK). GK differs from other hexokinase isoforms in that it is not
allosterically inhibited by its own product, G6P; as well as having a higher Michaelis constant
(Km) for glucose 49,51. Additionally, GK is also controlled through interaction with its own
regulatory protein, glucokinase regulatory protein (GKRP), which in combination with glycolytic
metabolite fructose-6-phosphate (F6P), acts to bind and inhibit GK activity 59,60. More elaborate
control mechanisms are also important for modulating GK activity as there is evidence of this
step being rate limiting in glycogen synthesis 61. This is important in the liver because it is the
site of not only glucose storage, but in times of excess, conversion of glucose into fatty acids 62.
As glucose uptake is dependent upon the concentration gradient between the hepatocyte and the
blood, a high rate of glucose phosphorylation to G6P is critical to maintain a low concentration of
free glucose within hepatocytes, and subsequent glucose uptake. However, when glycogen stores
are full, high glycolytic flux (and subsequently, high F6P) can feedback to GK to slow glucose
uptake and prevent conversion to fat 62–64.
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There are two primary fates for G6P, glycolysis and glycogen synthesis. Glycolysis
utilizes G6P, and, through a series of reactions, converts it into two molecules of pyruvate, two
ATP molecules and four reducing equivalents in the form of NADH. Pyruvate, depending on the
environment, can be converted to lactate when the overall energy state of the cell is low (a
shortage of NAD+) or into acetyl-coenzyme A (acetyl-CoA), which in turn is metabolized in the
citric acid cycle to produce additional NADH for electron transport and oxidative
phosphorylation. If directed towards glycogen synthesis, G6P is converted to G1P and then in the
glycogenic substrate, UDPG, by phosphoglucomutase and UDPG pyrophosphorylase,
respectively 51.
When conditions favour glycogen synthesis, such as following a carbohydrate-containing
meal, glucose units will be funneled towards storage. This requires the combined control of two
regulatory enzymes, glycogen synthase (GS) and glycogen phosphorylase (GP). Activation of
GS is mediated by both allosteric and covalent mechanisms 44,49. Glucose and glucose
metabolites account for the allosteric modulation while insulin signalling is the main covalent
effector 49. GS is a homodimer and exists in two states, an active a form and an inactive b form.
Phosphorylation occurs through the activity of a variety of protein kinases including protein
kinase A (PKA), AKT (also known as protein kinase B (PKB)), glycogen synthase kinase 3
(GSK3), calmodulin dependent protein kinase (CamK), protein kinase C (PKC) and adenosine
monophosphate dependent protein kinase (AMPK) among others 49,65,66. Phosphorylation of any
of GS’ six possible sites acts to convert the a form to the b form, decreasing its maximal rate
(Vmax) of catalysis 49. This illustrates a key difference between the muscle and liver isoforms of
GS as phosphorylation of the muscle isoform decreases its affinity towards its substrate UDPG,
not the maximal rate of catalysis as in the liver isoform 49. Additionally, G6P is a potent activator
of the b form of GS, such that maximal activity of G6P through the exposure of the enzyme to
supraphysiological conditions results in equivalent rates of glycogen synthesis as seen with the
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active a form of the enzyme 49. In addition, intracellular localization is also different between the
muscle and liver isoforms of GS 67. GS translocates from a diffuse distribution in the cytosol
towards the cell periphery in hepatocytes; whereas in the muscle, it moves from the nucleus into
the cytosol to synthesize glycogen67–69.

1.5

Modulators of Glycogen Synthase Activity
1.5.1

Glucose Induced Glycogen Synthesis

The first mechanism by which elevated levels of intracellular glucose can increase the
rate of glycogen synthesis is through interaction with GP (see figure 1.2). The active form of GP
acts as a glucose sensor, binding to free glucose which competitively inhibits the enzymes active
site and alters GP conformation 49,70. Conformational changes in GP have a twofold effect as it
increases the rate of GP dephosphorylation (and inactivation) and disrupts the complex that forms
between active GP and the primary GS phosphatase, phosphoprotein phosphatase 1 (PP1) 49,70.
Dissociation of PP1 allows this protein to dephosphorylate and activate GS. In addition, glucose
is an important regulator of the GK-GKRP interaction. Increases in glucose concentration have
been shown to free GK from this complex to increase the production of G6P, another potent GS
activator 71,72. As mentioned above, G6P allosterically activates GS b by increasing the rate of
GS dephosphorylation and directly interacting with the enzyme 71. Finally, as previously
discussed, glucose is also a regulator of GS localization, causing it to move to sites of glycogen
storage.
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Figure 1.2 Modulators of Glycogen Synthesis. GS activity is altered by a variety of signals
including covalent phosphorylation by the insulin signalling (inhibitory) cascade as well as
small metabolite allosteric control.
Abbreviations: IRS, insulin receptor substrate; PI3K, phosphatidylinositol phosphate kinase;
IP2 Inositol diphosphate, IP3, Inositol triphosphate; PDK, phosphoinositide dependent protein
kinase; GSK3β, glycogen synthase kinase 3β; GS, glycogen synthase, GKRP, glucokinase
regulatory protein; GK, glucokinase; PP1, phosphoprotein phosphatase 1; GP, glycogen
phosphorylase; ERK, extracellular regulated kinase; JNK, c-jun n-terminal kinase; NFκB,
nuclear factor kappa B; PKC, protein kinase C; PKA, protein kinase A; AMPK, adenosine
monophosphate dependent kinase, CAMK, calmodulin dependent protein kinase
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1.5.2

Insulin Signalling

Insulin signalling is responsible for controlling many intracellular processes, including
glucose metabolism and is illustrated in figure 2.2 73. The insulin receptor (IR) is a ubiquitously
expressed, heterodimeric receptor, belonging to the receptor tyrosine kinase (RTK) superfamily.
IR activation leads to the stimulation of both canonical arms of the insulin signalling pathway, the
metabolic phosphatidylinositol-3 kinase (PI3K) - AKT nodule; and the mitogenic ras-mitogen
activated protein kinase (MAPK) signalling pathways 74,75. As the AKT side of this pathway is
primarily responsible for regulating glucose metabolism, it will be the focus of the following
section. It should be noted however, that despite the apparent divergence of these two cascades,
significant cross-talk exists, contributing to the complexity of insulin signalling network 73.
Circulating insulin binds to the (extracellular) α subunit of the insulin receptor, causing
the autophosphorylation of tyrosine residues in the intracellular β subunit, creating an active
docking site for insulin receptor substrate (IRS) proteins 76. The IRS family contains six
members (dubbed IRS 1-6), of which, IRS1 and IRS2 are the most widely expressed in both the
liver and skeletal muscle 73,77,78. IRS proteins then bind to phosphorylated tyrosine residues on
the activated IR 73,78,79. IR-IRS interaction promote phosphorylation of one or more of IRS’
approximately twenty tyrosine residues, allowing interaction with the p85/p55 regulatory subunit
of PI3K79. Subsequent activation of the p110 kinase domain of PI3K allows the conversion of
phosphatidylinositol diphosphate (PIP2) to the active second messenger phosphatidylinositol
triphosphate (PIP3). PIP3 then binds to and activates 3-phosphoinositide dependent kinase (PDK)
which phosphorylates 2 residues (a serine and a threonine) to activate AKT 73.
AKT is the principle mediator of an insulin signal as it is capable of mediating changes in
other kinases, signalling molecules and transcription factors. GSK3 is a key effector on glycogen
metabolism and is down regulated by AKT phosphorylation 73. This decreases its capacity to
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phosphorylate and inactivate GS, favouring glycogen synthesis 49. GSK3 exists in two isoforms,
GSK3α and GSK3β. The two forms share high levels of sequence homology within their kinase
domains but little throughout the rest of the protein and have largely redundant functions 80.
GSK3 is an important regulator of many intracellular processes with over 40 recognized putative
substrates including transcription factors, structural proteins involved in cell motility and
trafficking as well as metabolic substrates such as GS 80. GSK3 is controlled by reversible
phosphorylation (as in the insulin cascade outlined above as well as in pathways controlled by Gprotein coupled receptors); as well as by intracellular localization (nuclear GSK3 is more active
than cytosolic GSK3) and its association with signalling complexes (seen in its role in Wnt-β
Catenin signalling) 80. It should be noted that, unlike traditional positive regulation by
phosphorylation, serine phosphorylation, such as that mediated by AKT, of GSK3 decreases its
activity toward its substrates 80.

1.6

Insulin Resistance
Insulin resistance is a condition in which peripheral tissues are unable to properly

respond to the insulin hormone. Resistance to insulin has profound consequences not only to
glucose metabolism but other metabolic signalling pathways (lipolysis/fatty acid metabolism,
transcription, translation, etc.) influenced by the insulin hormone as well. While common to both
T1DM and T2DM, the origin of the disease appears to differ. Insulin resistance seems to
preclude the development of T2DM as it has been evident in patients 10 to 20 years prior to the
onset of clinical hyperglycemia 81. Tissue resistance to insulin causes islet β-cells to secrete
progressively higher levels of insulin, which eventually causes β-cells to fail, resulting in overt
hyperglycemia and T2DM 82. On the other hand, T1DM begins with immune-related β-cell
death and insulin resistance manifests later in the progression of the disease, impairing the
efficacy of administered insulin in controlling blood glucose concentrations 83.
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Despite etiological differences, a possible mechanism is similar between these two
conditions and revolves around decreased insulin-induced, IRS mediated PI3K activation 73,81.
This effectively decreases overall insulin signalling as it decreases the activity of AKT, the
principle effector on both glucose uptake and glycogen synthesis. The exact mechanism behind
this has yet to be fully elucidated; however, increased levels of IRS serine phosphorylation are
seen in insulin resistant states and have been implicated 73. IRS proteins contain over 70 potential
serine phosphorylation sites capable of modifying its activity. Interestingly, insulin-responsive
kinases including extracellular regulated kinase (ERK), S6 kinase, c-jun N-terminal kinase (JNK)
and nuclear factor kappa B kinase (NFκB) are all known to phosphorylate serine residues within
IRS proteins, indicating a feedback mechanism to limit an insulin signal 84–87. These proteins are
also positively controlled by levels of circulating cytokines as well as fatty acids, creating a
causative link between fat metabolism/obesity and insulin resistance 73,81,88,89. In addition,
alterations in insulin receptor phosphorylation, decreased ability for insulin to bind its receptor
and depleted intracellular pools of IR have also been cited as potential mechanisms underlying
insulin resistance 87,90.

1.6.1

Hepatic Insulin Resistance

The IR represents the first step in transducing an insulin signal into intracellular events
and as such, plays a key role in insulin resistance 91. Hepatic IR knockout (known as LIRKO)
mice demonstrate severe insulin resistance and dysfunctional glucose production and gene
expression 91. Recent work utilizing another genetically-induced model of hepatic insulin
resistance in which NFκB is constitutively active have shed further light on the matter.
Hyperactive NFκB mimics the subacute inflammatory state seen in the fatty livers of patients
with T2DM.87. Evidence from this model has demonstrated decreased basal and insulinstimulated IR and IRS2 tyr-phosphorylation, decreased insulin-induced suppression of hepatic
glucose production, decreased glycogen storage and impaired GSK-3β phosphorylation 87. The
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gluconeogenic response to feeding was also disrupted such that glucose-6 phosphatase (G6Pase)
and phosphoenolpyruvate carboxykinase (PEPCK) mRNAs were inappropriately elevated
postprandially 87. NFκB activation also increased mRNA production of pro-inflammatory
cytokines interleukin (IL) 1B and IL6 as well as cytokine receptors for IL1, IL6, IL8 and toll-like
receptor (TLR) 2 87. These were shown to feedback to the liver itself as mRNAs for Stat3 and
SOCS1, 2 and 3 were elevated 87. Despite hepatic-specific NFκB activation, systemic effects in
skeletal muscle were also observed as IRS1 phosphorylation, glucose uptake and glycogen
synthesis were all impaired, lending support to the idea that insulin resistance could potentially
begin in the liver and travel systemically 87,92.
T1DM is associated with both peripheral and hepatic insulin resistance. Early work from
DeFronzo et al demonstrated that, during hyperinsulinemia, patients with T1DM had higher
levels of endogenous glucose production than healthy control subjects, indicative of the liver’s
inability to respond to insulin 93. These results have been confirmed more recently by several
groups reporting that T1DM patients with long term continuous subcutaneous insulin therapy
(CSII) had deficits in suppression of endogenous glucose production (EGP). Furthermore,
following overnight normalization of blood glucose concentrations, patients with T1DM required
significantly more insulin to supress hepatic glucose production 94,95. Despite a lack of
mechanistic studies in T1DM, potential links can be drawn between recent works. Insulin
resistance in T2DM has long been associated with obesity, specifically alterations in lipid
partitioning such that abnormal amounts of lipid accumulate in the liver and skeletal muscle. A
mouse model lacking adipose tissue was created and mimicked this response by causing
significant fat accumulation in the liver and skeletal muscle; and insulin resistance 96. Despite
lack of obesity, recent work using liver biopsies from T1DM patients has demonstrated that over
50% demonstrate steatosis, 20% had non-alcoholic fatty liver disease and over 70% had fibrotic
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scarring 97. This is the first study to date demonstrating this in T1DM and may provide insight
into the origin of insulin resistance in this condition.

1.7

Diabetes and Glycogen Storage
While patients with T1DM are likely to experience both fed and fasting hyperglycemia,

they are also susceptible to the development of insulin- and exercise-mediated hypoglycemia.
Despite the seemingly opposite nature of these conditions, it has been suggested that deficits in
hepatic glycogen storage contribute to both 17. Early work by Hwang et al, demonstrated using
C13 magnetic resonance spectroscopy that, following ingestion of isocaloric meals (breakfast,
lunch and dinner), patients with T1DM stored less liver glycogen after each individual meal
(measured 4hrs later) as well as accumulated less total glycogen (approximately 70% less) over
the course of the day 17. This same study also demonstrated that T1DM subjects synthesized only
41% of their daily liver glycogen from the direct pathway; whereas healthy control subjects
synthesized 65% from direct sources 17. The authors conclude that alterations in the
insulin:glucagon ratio (T1DM subjects were hypoinsulinemic and hyperglucagonemic following
each meal relative to the controls) likely contribute to this deficit but acknowledge that hepatic
alterations in T1DM are also likely. Decrements in glycogen storage and direct:indirect pathway
flux is a strong candidate for postprandial hyperglycemia as increased gluconeogenic activity and
glucose release, combined with impaired glucose uptake/storage leaves absorbed glucose
nowhere to go. Later work from Kishore and colleagues connected these findings to impairments
in hypoglycemic recovery 18. They found that, during a hypoglycemic clamp in which patients
blood glucose was held constant at ~3.33mM by insulin infusion, patients with T1DM were
unable to increase the rate of endogenous glucose production (total of hepatic glycogenolysis and
gluconeogenesis) due to the complete inability to utilize hepatic glycogen 18. It was concluded
that a 30% decrement in baseline hepatic glycogen relative to control subjects, in addition to
defects in hormonal counterregulation (lower epinephrine, norepinephrine and glucagon were
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observed during hypoglycemia) were the cause of impaired response to hypoglycemia in
T1DM18.
While patients with T1DM in the above studies were insulin treated, there was still some
doubt as to whether intensive insulin treatment could normalize hepatic glycogen content.
Consecutive works from Bischoff et al set out to answer this question 98,99. The first of the two
experiments examined if short-term intensive insulin therapy could normalize the alterations in
hepatic glycogen metabolism seen in T1DM. Untreated subjects with T1DM showed lower rates
of both glycogen synthesis and breakdown (74% and 41% respectively, relative to healthy
subjects), both of which were significantly improved with intensive insulin treatment98. The
second experiment utilized similar short-term insulin treatment in addition to a full week of
treatment prior to the study during which T1DM patients were normoglycemic. Rates of hepatic
glycogen synthesis were normalized to the level of control subjects; however, the proportion of
direct-to-indirect synthesis was still favouring indirect synthesis in the patients with T1DM 99.
This finding in patients with long term T1DM is in opposition to more recent work in an STZinduced model of rodent diabetes. Soares et al (2012) found that, when insulin was administered
9 days post Streptozotocin (STZ), by day 18 (post STZ) the rates of direct pathway glycogen
synthesis were normalized in the rats with T1DM 100. This suggests that, if intensive insulin
therapy is started early following the onset of T1D, the hepatic defects seen in long standing T1D
may in fact be reversible.
Insulin signalling and glycogen storage in T1DM is associated with deficits in the
expression and activation of many proteins involved in hepatic glycogen synthesis. LibalWeksler et al (2001) recently demonstrated that STZ-induced diabetic animals had lower total
and activated GS activity relative to healthy animals and that insulin stimulation was unable to
increase GS activity in vitro 101. Despite this, they found that the total amount of GS protein was
equivalent between the two conditions and that insulin stimulation increased GS protein content
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in both groups 101. This is interesting as it suggests that insulin’s effects on protein production are
functional in this model of T1DM, but its ability to increase enzyme activity is hindered. These
results were verified in the same study using two dietary models of insulin resistance, high fat and
high simple sugar diets. Both induced decreases in GS activity 101. This is of particular interest
as hyperglycemia is also a known characteristic of T1DM and, despite the presence of insulin
secretion, glucose was also able to decrease GS activity 101.
Work from Gannon and Nuttall, however, have shown that GS activity is increased in
T1DM as a function of duration of the disease 102. Specific activity and GS mRNA were
increased in T1DM after both 3 and 8 days of the disease 102. This occurred despite only small
changes in total GS content and was unchanged with feeding or fasting 102. It was concluded that
T1DM increases the efficiency of the enzyme as enzyme mass and mRNA could not explain the
change in activity. Furthermore, by day 8, protein mass and mRNA were lower than that seen in
controls animals 102. Enzyme activity was also equivalent in the fed and fasted state, yet mRNA
and protein contents differed, hence, changes in enzyme phosphorylation and activation by G6P
were cited as to why enzyme activity was increased. This work is not the only to contradict
Libal-Weksler and colleagues. Increases in GS activity in T1DM have been reported by several
groups as well as in differing diabetic models including STZ and alloxan-induced diabetes 103–107.
Despite apparent increases in GS activity, T1DM animals in the aforementioned works
had significantly decreased hepatic glycogen levels and no change in GS content at both 3 and 8
days 102. This is interesting as increases in GS protein content by adenoviral overexpression have
been shown to increase hepatic glycogen storage 108. As simple overexpression of GS is clearly
unable to account for all changes accompanying the hepatic proteome in T1DM, direct
comparisons are unfounded; however, it does raise interest as to what else might be causing the
deficit in glycogen storage.

21
Differences in the above studies are likely due to differences in T1DM model as well as
disease duration. In vitro versus in vivo activity analyses yield seemingly conflicting results as
cell culture of diabetic hepatocytes suggests decreases in GS activity while hepatocytes from
whole-animal livers suggest an increase 101,102. Reasons for these discrepancies are unclear but
may be due to differences in the hormonal and neural input to an intact liver, causing alterations
in enzyme activity not mimicked by culture media. Additionally, studies in T1DM animals
without insulin treatment remove a key hormonal stimulus for GS activation that has been
reported to be impaired in vitro 101. Additionally, the duration of diabetes, as well as the severity,
has also been shown to change GS activity 102. Durations up to 8 days as used by Gannon and
Nuttall demonstrate increased GS activity, however Rao and colleagues found, in insulin treated
animals after three weeks of diabetes, that GS activity and expression were unchanged from
control levels 109. To date, no studies on long term diabetes and GS activity or expression have
been conducted but if the trend of decreased activity from 8 to 21 days continues, it is possible
that GS activity would be decreased relative to control levels and may be a contributing factor to
decreased levels of hepatic glycogen.
In addition to GS, other proteins involved in hepatic glycogen synthesis have been shown
to be altered in T1DM. GLUT2 protein and mRNA content appears to be stable in T1DM
patients and is largely unchanged with insulin administration 110. Additionally, although feeding
and fasting have been known to alter GLUT2 mRNA, there is little change in protein content
57,110

. Despite these findings, Libal-Weksler et al have shown that, in cultured hepatocytes, both

high sugar and high fat feeding decreased GLUT2 protein content, which, consistent with
additional works, was not improved by acute insulin administration 49,57. This is an interesting
finding as glucose has also been shown to increase GLUT2 mRNA content in hepatocyteswhich
suggests a post-transcriptional control mechanism is dominant in GLUT2 expression111.
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Downstream of GLUT2, GK is an important regulator of glycogen synthesis in the liver.
Adenoviral overexpression of GK in hepatocytes has been shown to significantly increase
glycogen storage, independent of GS content or activity 61,108,112. Insulin is the primary factor
responsible for increasing GK content in hepatocytes, and accordingly, insulin deficient STZinduced T1DM animals have significantly lower levels of GK; and humans deficient for GK
develop maturity onset diabetes of the young (MODY) type 2 51,113–115. Furthermore, obese
T2DM patients also have decreased levels of GK, indicating once again GK’s importance in
whole body glucose homeostasis 116. Insulin administration to T1DM subjects has been shown to
normalize both GK content and activity, and overexpression in diabetic animals also restores both
blood glucose concentration and glycogen content, as well as the animals ability to avoid
hypoglycemia during a fast 100,115.
In addition to alterations in direct pathway glycogen storage, T1DM is also known to
generate significant amounts of glycogen by the indirect pathway. Proteins involved in the
gluconeogenic production of G6P are also altered in T1DM. Soares and colleagues noted, in a
short-term insulin treated, STZ-induced diabetic model, that T1DM animals (with or without
insulin) demonstrated significant increases in the mRNA content of gluconeogenic proteins
PEPCK, fructose-1,6-bisphosphatase (F6Pase) and G6Pase 100.

1.8

Exercise and Glycogen
Physical exercise is a metabolic stressor well known to improve insulin sensitivity as well

as alter substrate utilization, increase lean muscle mass and decrease fat mass 117,118. Exercise
also produces alterations in key metabolic enzyme concentrations and activities, as well as
cardiac and respiratory efficiency, allowing better performance in subsequent exercise bouts.
Muscle glycogen is used in an intensity and duration dependent manner to fuel muscle
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contractions; and loss of glycogen is associated with exhaustion and withdrawal from exercise 119.
During and following an exercise bout, muscle glucose uptake is increased in an insulinindependent fashion which functions to both provide glucose for glycolysis during exercise, and
substrate for glycogen resynthesis following exercise 119,120. Following long term training
programs, increases in oxidative enzyme capacity generate a glycogen-sparing effect such that a
greater proportion of energy can be obtained from fatty acids at increasingly higher intensities.
Additionally, exercise training also increases the overall storage capacity for muscle glycogen 121.
With respect to function in blood glucose maintenance, hepatic glycogen storage and use with
both acute and prolonged training will be the focus of the following section.

1.8.1

Acute Exercise

Stored hepatic glycogen is utilized for the maintenance of blood glucose concentrations
in times of increased use, not for fueling muscle contractions. Earlier studies from Ivey and
colleagues demonstrated significant glycogen use in skeletal muscle but not the liver during 5
minutes of intense treadmill exercise 122. Exercise of this short duration is unlikely to be long
enough for blood glucose to become a significant contributor to exercise energy production,
leaving hepatic glycogen untouched. However, following the bout, liver glycogen was depleted
over the following four hours, while significant glycogen accumulated in muscle 122. Studies
utilizing prolonged low-intensity or high-intensity exercise to exhaustion, however, demonstrate
complete depletion of hepatic glycogen 123–127. Following an acute exercise bout, very little
hepatic glycogen is resynthesized in the absence of food intake, and by 24 hours post-exercise,
glycogen concentrations are lower than those seen following 36 hours of fasting 124. In a follow
up study, animals were followed for 24 hours and again, during the first four hours following
either continuous or intermittent exercise to exhaustion, no hepatic glycogen was stored when
food was restricted 127. Despite this, skeletal muscle glycogen concentrations increased in this
time frame to approximately 50% of resting levels 127. When food was provided ad libitum for
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the following 20 hours, liver glycogen returned to the level of an exercised rat, but not to the level
of a non-exercised control rat 127. In this same time frame however, muscle glycogen was seen to
reach approximately 190% of pre-exercise resting values, suggestive of preferential resynthesis in
muscle over the liver 126,127.

1.8.2

Exercise Training

Exercise training has been established to increase hepatic glycogen storage 128,129.
Baldwin and coworkers demonstrated increased resting hepatic glycogen levels in rats following
14 weeks of swimming, 6 hours per day, 5 days a week 129. This improvement was also
associated with a smaller decrease in liver glycogen following a 45 min progressive treadmill test
129

. In contrast to the extreme endurance activity used in those studies, only 6 weeks of treadmill

running, 6 weeks of weighted jumps (4 sets of 10, 5 days per week) and 12 weeks of ladder
climbing (4-8 climbs, 3 days per week) have all be shown to increase liver glycogen stores 130,131.
Additionally, exercise training supplemented with either a diet high in fructose or whey protein,
have also been shown to further increase liver glycogen 132–134. In addition to alterations in
hepatic glycogen content, exercise training has also been shown to increase GS activity, in
conjunction with increases in liver size, further enhancing the capacity of the liver to store
glycogen 128. Contrary to these findings, work from James and colleagues found that 10 weeks of
treadmill running at a light, moderate or high intensity did not alter glycogen content or GS
activity in the liver 135.

1.9

Summary
Patients with T1DM suffer from hepatic glycogen deficits, which alter their ability to

increase glucose release during a hypoglycemic episode. Additionally, hepatic insulin resistance
is present and may contribute to the lack of hepatic glycogen stores. Exercise training has been
shown to improve a host of T1DM-related complications, however many patients refrain from
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exercise due to fear of hypoglycemia. Training studies have demonstrated that exercise might act
as a means of increasing hepatic glycogen storage and would aid in hypoglycemia prevention and
recovery. Further study is required to elucidate molecular mechanisms involved in both the
glycogen deficit and hepatic-insulin resistance noted in patients with T1DM and to examine the
effects of exercise training on these parameters.
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CHAPTER 2

2.1

Introduction
Type 1 diabetes mellitus (T1DM) is characterized by the autoimmune destruction of

pancreatic islet β-cells, resulting in inadequate insulin secretion and deficits in blood glucose
control. As a result, many T1DM patients suffer from a variety of complications including
cardiovascular disease, retinopathy, neuropathy and nephropathy; as well as insulin resistance 1,2.
While it has been shown that strict control of blood glucose concentrations (4-7mM) through
intensive insulin therapy is effective in preventing many of these complications, many patients
refrain from strict control and maintain more moderate levels of glycemia (8-11mM, known as
conventional insulin therapy) to prevent insulin overcorrection and subsequent hypoglycemia 1.
In addition to intensive insulin therapy, physical activity has been shown to be effective in
relieving many T1DM-related complications. However, patients refrain due to fear of exercise
induced hypoglycemia 3–5.
It is believed that a deficit in hepatic glycogen stores may, in part, be responsible for the
inability of patients’ with T1DM to respond to a hypoglycemic episode 6. Hepatic glycogen,
unlike that in muscle, is stored for the maintenance of blood glucose concentrations in times when
glucose homeostasis is challenged, such as during a fast or following exercise. Early work from
Hwang et al. (1995) demonstrated that, following a meal, patients with T1DM synthesized
significantly less hepatic glycogen than healthy subjects. Furthermore, a larger proportion of that
glycogen came from indirect synthesis 6. It was concluded that this was largely due to disruptions
in the insulin:glucagon ratio following a meal 6. Glycogen deficits are also seen to persist
following short term intensive insulin therapy, however, following a week of normoglycemia,
hepatic glycogen levels have been shown to return to those of a healthy subject 7,8. Lack of
hepatic glycogen stores can be connected to impairments in hypoglycemic recovery. Under a
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hypoglycemic clamp, rats with T1DM are completely unable to mobilize hepatic glycogen,
suggesting that inadequate hepatic release of glucose during hypoglycemia was a result of
insufficient glycogen at the start of the clamp 9.
Hepatocyte glucose uptake, unlike that seen in muscle, is mediated by the glucose
transporter 2 (GLUT2), an insulin insensitive isoform 10–12. Glucose is phosphorylated by
glucokinase (GK), a high affinity isoform of hexokinase, into glucose-6-phosphate (G6P) 10,13.
G6P is then converted to glucose-1-phosphate (G1P), uridine diphosphate-glucose (UDPG) and
ultimately converted into glycogen by glycogen synthase (GS) 10. All three of these proteins have
been shown to modulate hepatic glycogen concentrations and aberrant expression or activity may
underlie defective glycogen synthesis 14–17. These proteins have also been demonstrated to be
disrupted in T1DM, although conflicting results have been shown due to differences in diabetic
model, as well as disease duration 18–22. In addition to alterations in glycogen synthesizing
proteins, hepatic insulin resistance may also have a role in impaired glycogen synthesis. Work
from Defranzo et al originally demonstrated hepatic insulin resistance in T1DM as demonstrated
by reduced suppression of hepatic glucose production by insulin; a finding which has recently
been supported by others 23,24. Although no mechanistic studies exist in patients with T1DM, a
rodent model of hepatic insulin resistance, in which hepatic nuclear factor kappa B (NFκB) is
constitutively active, exhibits disruptions in insulin signaling and glycogen storage. More
specifically, the activation of insulin receptor substrates (IRS) and glycogen synthase kinase
(GSK)-3β were shown to be reduced 25.
Exercise training has been shown to mitigate many of the complications associated with
T1DM and, in healthy populations, also alters hepatic glycogen metabolism. Recent studies have
demonstrated the efficacy of various exercise programs, including aerobic and resistance
exercise, in increasing hepatic glycogen stores as well as glycogen synthase (GS) activity 26–29.
However, limited work has been completed in T1DM models30. Following high intensity
exercise, patients with T1DM, despite having lower basal hepatic glycogen contents, have similar
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rates of glycogenolysis, and higher rates of gluconeogenesis compared to healthy control subjects
31

. Similar rates of glycogenolysis suggest that that if basal glycogen levels had been higher, any

drop in glycemia following exercise might have been shorter in duration and/or magnitude, or
preventable altogether.
The purpose of the current investigation was to determine if a 10-week aerobic exercise
training program could improve hepatic glycogen storage in rats with T1DM and whether
improved glycogen storage was associated with changes in expression of glycogen-synthesizing
proteins. Furthermore, a secondary aim of the study was to determine if aerobic training was able
to alter the insulin signaling pathways mediating glycogen storage in the liver. It was
hypothesized that exercise training would increase hepatic glycogen storage as well as glycogenic
protein expression, and that this would be associated with improvements in hepatic insulin
signaling.

2.2

Methods

Ethics approval
In accordance with the guidelines of the Canadian Council on Animal Care, this study
was approved by the University Council of Animal Care and Research Ethics boards of the
University of Western Ontario (Appendix B1).

Animals
Eight week old, male Sprague-Dawley rats were obtained from Charles River
Laboratories (St. Constant, QC, Canada). Animals were housed two per cage in standard rat
cages and kept on a 12-hour light/dark cycle at constant temperature and humidity (20±1°C, 50%
respectively). Food (protein=26%, carbohydrate=60%, fat=14%; enriched with vitamins and
minerals; 164 PROLAB RMH 3000, Brentwood, MO, USA) and water were given ad libitum for
the duration of the study. Rats were divided into four experimental groups: non-T1DM sedentary
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(C, n=16), non-T1DM exercised (CX, n=16), T1DM sedentary (D, n=16), and T1DM exercised
(DX, n=16). (See Figure 2.1)

Experimental Procedures
Diabetes Induction
T1DM was induced using multiple low dose streptozotocin (STZ) injections (Appendix
A1) to replicate conditions seen in T1DM patients 32. On five consecutive days, 20mg/kg of STZ,
dissolved in citrate buffer (0.1M, pH 4.5), was given intraperitoneally (IP). T1DM was then
confirmed by two consecutive non-fasted blood glucose readings of >18mM. If, after five
injections, T1DM was not confirmed, additional injections were given until confirmation was
obtained. Blood glucose was then maintained in the range of 9-15mM using insulin pellets, to
represent that under conventional insulin treatment 33. Exogenous insulin pellets (1 pellet; 2U
insulin/day; Linplant, Linshin Canada, Inc., Toronto, Ontario, Canada) were subcutaneously
implanted in the abdominal region (Appendix A2).
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Figure 2.1 Study Design
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Exercise Protocol
One week prior to the start of exercise training, animals were familiarized with the
treadmill to allow rats to become accustomed to both the treadmill and to running itself.
Familiarization consisted of 15min of progressive running up to 30m/min over two days.
Following the familiarization period, the exercise training consisted of 1hr of treadmill running, 5
days per week, at 27m/min on a 6% gradient for 10 weeks. This intensity of exercise has
previously been shown to elicit 70-80% of the animals’ VO2max 34.

Experimental Measures
Euglycemic Hyperinsulinemic Clamp
Eight animals from each group were utilized for the euglycemic-hyperinsulinemic clamp.
Clamp experiments were initiated three days following the final bout of exercise training. Prior
to clamp studies, animals were fasted for 12hrs. Anesthetization consisted of inhaled isoflurane
gas (4%) as well as an IP injection of urethane (25mg/kg) and α-chloralose (4mg/kg). Isoflurane
gas was removed after approximately 20min and urethane α-chloralose maintained
anesthetization during the clamp. A catheter was inserted into the right jugular vein to facilitate
infusions of anesthetic, insulin (10mU/kg/min; 0.4 μIU/mL; Eli Lilly, Toronto, ON, CAN) and
glucose (20 mg/kg/min, 0.2 g/mL; EMD Millipore, Darmstadt, HE, Germany). Body temperature
was maintained at 37°C with a heating pad and was assessed by a rectal thermometer.
Clamp procedures were originally described by DeForonzo et al. (1979)35. Rats were
stabilized for 1hr prior to initiation of clamp experiments. Insulin (10mU/kg/min) was infused
using an infusion pump and blood glucose was maintained at basal blood glucose concentration
using variable infusions based on glucose measures (FreeStyle Lite, Abbot Diabetes Care,
Alameda, CA) every 5min for the first 20min and every 10min thereafter.
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Tissue Collection
Animals were euthanized by exsanguination immediately following the cessation of the
insulin clamp, where liver and muscle samples were quickly extracted. To remove the effects of
insulin clamp on tissue analysis, eight of the sixteen did not undergo the clamp procedure and
were sacrificed (isoflurane anesthesia followed immediately by exsanguination) three days
following their last bout of exercise for extraction of liver and muscle tissues samples. Upon
extraction, all liver and muscle tissues were immediately flash frozen in liquid nitrogen and
stored at -70°C for further analysis.

Glycogen Quantification
Liver and muscle glycogen content was determined spectrophotometrically as described
by Lo et al. (1970 )36. Briefly, liver samples were homogenized in 30% KOH, saturated with
Na2SO4 and boiled for 30min. Glycogen was then precipitated in 95% ethanol and centrifuged at
3000rpm for 25min. Supernatants were discarded and the glycogen pellet was resuspended in
3ml of water and split into three, 1ml aliquots for triplicate analysis. 1ml of 5% phenol and 5ml
concentrated sulfuric acid (96-98%) were added sequentially, allowed to stand for 10min,
agitated, and incubated for 20min at 25-30°C. The colour reaction was then analyzed using a
spectrophotometer at a wavelength of 490nm.

Immuno Blot Analysis
Liver samples were homogenized at a 1:10 (weight : volume) ratio in homogenizing
buffer containing 100mM tris, 0.1mM EDTA, 0.1mM EGTA, 1% triton-X 100, 1% phosphatase
inhibitor, 1% protease inhibitor, pH 7.5. Loading volumes were determined using the Bradford
protein assay.
Proteins were run on polyacrylamide gels (10% separating, 4% stacking) at a constant
voltage (125V) for approximately 90min in running buffer containing 25mM tris, 200mM L-
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glycine and 0.1& SDS, pH 8.3. Proteins were then transferred to nitrocellulose membranes,
blocked for 4 hours at 4°C in 10% non-fat dry milk, 1% BSA and probed with primary antibodies
(anti-GS, anti-IR and anti-pGSK-3β were from Cell Signaling; anti-GLK, anti-GLUT2 and antiPEPCK from abcam and anti-GSK-3β was from Santa Cruz) overnight. Membranes were then
washed and incubated for 1 hour in horseradish-peroxidase conjugated secondary antibodies and
detected using luminol-based chemiluminescence in a chemidoc imager (BioRad). Optical
densities were quantified in BioRad Quantity One software. Total GS protein content was shown
as the additive total of the two bands detected.

Statistical Analysis
Basic characteristics, glycogen contents and western blot group differences were tested
using a two-way ANOVA and tukey’s post hoc test. Group differences for the euglycemichyperinsulinemic clamp were assessed using a repeated measures two-way ANOVA.
Significance was declared with α set to 0.05.

2.3

Results

Animal Characteristics
Animal weights and weekly blood glucose values are shown from weeks 1 and 10 in
table 2.1. There were main effects of diabetes on blood glucose levels such that T1DM animals
had higher blood glucose concentrations at both weeks 1 and 10 (p<0.05). No effects of exercise
were seen at either week 1 or 10 (p>0.05). Body weights were significantly lower in animals
with T1DM at both weeks 1 and 10 (p<0.05) and exercised animals also weighed significantly
less than unexercised counterparts at these time points (p<0.05). These data have also been
reported elsewhere 37,38.
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Liver Glycogen
There was a main effect for T1DM on the hepatic glycogen content (p<0.05; figure 2.2)
such that rats with T1DM had lower liver glycogen contents than those without T1DM. 10 weeks
of aerobic exercise training had no effect on liver glycogen levels (p>0.05; figure 2.2).

Protein Expression
To determine if aberrant expression of glycogenic proteins could underlie discrepancies
in hepatic glycogen storage in T1DM, GLUT2, GK and GS levels were quantified in the liver.
Neither T1DM nor exercise training significantly altered GLUT2 expression (p>0.05; figure 2.3).
GK was significantly increased in rats with T1DM (p<0.05; figure 2.4), while exercise training
had no effect (p>0.05; figure 2.4). There was a significant interaction between T1DM and
exercise (p<0.05; figure 2.5) with respect to total GS content. Pairwise comparisons indicate that
DX is significantly greater than D (p<0.05), no other differences were found. Finally, PEPCK
protein content was significantly elevated by T1DM (p<0.05, figure 2.6). No main effects were
found with exercise training (p>0.05, figure 2.6).

Euglycemic-hyperinsulinemic Clamp and Hepatic Insulin Signaling
Glucose infusion rates are shown in figure 2.7. Individual glucose infusion rates did not
change significantly for any group over the course of the clamp (p>0.05). There was a significant
main effect of groups on glucose infusion rate (p<0.05). Pairwise comparisons indicate that D is
significantly lower than C, CX and DX (p<0.05), C and DX are not significantly different from
each other (P>0.05) and CX is significantly higher than C, D and DX (p<0.05).

Prior to insulin stimulation, IR protein content was significantly elevated in rats with
T1DM compared to non-T1DM rats (p>0.05; figure 2.8). Exercise training had no effect on IR
protein content (p>0.05; figure 2.8). To examine if an insulin signal was being propagated down
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the insulin signaling cascade, phosphorylated GSK was examined following the insulin clamp.
There were no effects of either T1DM or exercise training on the phosphorylation of GSK
following insulin stimulation (p>0.05; figure 2.9).

Following the insulin clamp, liver and soleus glycogen contents were measured to
determine which tissues were responsible for glucose uptake. No effects of T1DM or exercise
training were observed for liver glycogen content (p>0.05; figure 2.10). Soleus glycogen was
found to be significantly increased by exercise training (p<0.05; figure 2.11), and no effects of
T1DM were observed (p>0.05; figure 2.11).
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Figure 2.2 Hepatic Glycogen Content. Glycogen content presented as mean ± SE.
An asterisk (*) indicates a significant main effect of diabetes (p<0.05), no effects of
exercise were found (p>0.05). n = 8, 8, 8, 6 for C, CX, D and DX respectively.
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Figure 2.3 Hepatic GLUT2 Protein Content. Hepatic GLUT2 transporter was
quantified using western blot analysis, normalized to the expression of β-actin and
presented as mean ± SE. Representative blots are shown in the same order as the
graph. No effects were found for either diabetes or exercise (p>0.05). n = 5 for
every group.
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Figure 2.4 Hepatic Glucokinase Protein Content. Glucokinase protein level was quantified
using western blot analysis, normalized to the expression of β-actin and presented as mean ±
SE. Representative blots are shown in the same order as on the graph. An asterisk (*)
indicates a significant main effect of diabetes (p<0.05), no effects of exercise were found
(p>0.05). n = 8 for C, CX and D, n = 7 for DX.
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Figure 2.5 Total Hepatic Glycogen Synthase Protein Content. GS protein content was
quantified using western blot analysis, normalized to the expression of β-actin and
presented as mean ± SE. Bands represent the muscle (top) and liver (bottom) isoform of
the GS protein. Bands were added together for quantification of total content.
Representative blots are shown in the same order as on the graph. A significant
interaction was found between diabetes and exercise (p<0.05). Pairwise comparison
indicates that DX is significantly greater than D (shown by an asterisk (*) p<0.05). n = 5
for all groups.
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Figure 2.6 Hepatic PEPCK Protein Content. PEPCK protein level was quantified using
western blot analysis, normalized to the expression of β-actin and presented as mean ± SE.
Representative blots are shown in the same order as on the graph. An asterisk (*)
indicates a significant main effect of diabetes (p<0.05), no effects of exercise were found
(p>0.05). n = 7 for all groups
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Figure 2.7 Glucose Infusion Rate during a Euglycemic-Hyperinsulinemic Clamp. During the
clamp, animal blood glucose was maintained at their basal level (~4mM for C and CX, ~15mM for D
and DX) using continuous infusion. Insulin was infused at a rate of 10mu/kg/min. Full circles (●)
represent C, open circles (○) are CX, full triangles () are D and open triangles (Δ) are DX. Data are
presented as mean ± SE. There was a significant effect of group (p<0.05). No effect of time was
observed (p>0.05). n = 7, 6, 9, 9 for C, CX, D and DX respectively.
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Figure 2.8 Hepatic Insulin Receptor Protein Content. Insulin receptor protein level was
quantified using western blot analysis, normalized to the expression of β-actin and presented
as mean ± SE. Representative blots are shown below in the same order as the graph. An
asterisk (*) indicates a significant main effect of diabetes (p<0.05), no effects of exercise were
found (p>0.05). n = 5 for all groups.
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Figure 2.9 Insulin-Induced Hepatic Glycogen Synthase Kinase 3β Phosphorylation.
Western blot analysis of GSK-3β phosphorylation was done on animals having undergone the
insulin clamp protocol to examine hepatic insulin signaling. Phospho-GSK-3β was
normalized to the total amount of GSK-3β and presented as mean ± SE. Representative blots
are shown in the same order as on the graph. No significant affects were observed (p>0.05)
for diabetes or exercise. N = 8, 8, 7, 6 for C, CX, D and DX respectively.

55

Figure 2.10 Post Insulin Clamp Hepatic Glycogen Content. Glycogen contents
are presented as mean ± SE. No significant effects for diabetes or exercise were
detected (p>0.05). n = 8, 8, 8, 6 for C, CX, D and DX respectively.
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Figure 2.11 Post Insulin Clamp Soleus Glycogen Content. Glycogen contents are
presented as mean ± SE. An asterisk (*) indicates a significant main effect of exercise
(p<0.05). No significant effects of diabetes (p>0.05) were observed. n = 8, 8, 7, 6 fr C, CX,
D and DX respectively.
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2.4

Discussion
Results of the current study indicate that 10 weeks of aerobic exercise training is not able

to reduce the hepatic glycogen deficit seen in rats with T1DM. Furthermore, proteins comprising
the direct and indirect pathway for glycogen synthesis, GLUT2, GK, GS and PEPCK, are all
present at levels equal to or in excess of those seen in healthy control animals. Finally, hepatic
insulin signaling appears to be intact in these animals as indicated by increases in IR content and
equivalent GSK-3β phosphorylation following insulin stimulation.
Early work has demonstrated that aerobic exercise training is able to increase hepatic
glycogen stores in healthy female rats by approximately 75% 27. Although mechanistic details
were not examined, it was suggested that increases in food intake by the exercised animals could
be driving the increase in glycogen storage 27. Additional work from Galbo et al. (1979)
demonstrated increased hepatic glycogen following aerobic training and noted higher basal GS
and lower glycogen phosphorylase (GP) activities in trained relative to untrained animals 26,28. It
is unclear why the control-exercised animals in the current study did not increase their hepatic
glycogen stores. Despite sex differences between studies, male and female rats have been shown
not to differ on both basal and post exercise liver glycogen levels 39. Differences in animal
sacrifice time post final exercise bout as well as exercise modality/duration of training may also
account for discrepancies. Both of the abovementioned studies demonstrating an exercisemediated increase in hepatic glycogen utilized swimming for up to 6 hours per day in contrast to
the 1 hour of running used in the present study; total training volume over the duration of the
study was also much greater and could account for the discrepancy 40.
In agreement with this argument, rats with T1DM in the current study had significantly
less liver glycogen than their healthy controls and this was not improved with exercise training.
Leme et al (2009) also demonstrated no increase in liver glycogen in animals with T1DM or in
healthy animals submitted to swim training 30. Animals in that study however, swam for 1 hour
per day and were sacrificed 2 days post exercise, as opposed to three days as done by Galbo 26,30.
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While it is understood that insulin promotes glycogen storage through the activation of GS,
insulin treatment in the current study was unable to restore/improve glycogen storage in rats with
T1DM. It is possible that, because normoglycemia was never achieved, treatment was
insufficient to restore glycogen levels. Furthermore, previous work from our laboratory
demonstrated that T1DM-exercised animals require less insulin than unexercised-T1DM, which
may account for the lack of glycogen storage 41. Additionally, subcutaneous insulin pellets
utilized in this study release insulin at a constant rate which has been shown to produce different
effects upon insulin signaling and subsequently, GS activation, than the pulsatile release seen
from a healthy pancreas which may account for the lack of treatment effect 42.
Work from Gannon and others has suggested that short term T1DM (lasting 8 days)
results in an increase in GS activity 19,43–45. In contrast, Rao and coworkers has demonstrated that
STZ-induced, insulin treated T1DM animals have equivalent GS activity and protein content to
healthy animals after three weeks of diabetes 20. To date no studies have examined the effects of
long term T1DM on GS activity. However, these aforementioned works do suggest GS activity
may actually decrease overtime, which, if continued over the long term may produce lowered
activity. Temporary increases in activity may also be indicative of a latency period in which the
disease has not fully developed and is consistent with studies demonstrating improvements and
even some reversals when interventions (insulin, exercise) are initiated very early in the
progression of the disease 22,46. To date no studies have been done examining if exercise training
can increase GS and/or decrease GP activities in patients with T1DM; however, a lack of hepatic
glycogen in diabetic-exercised animals suggests that GS activity might be lowered.
In the current study, proteins involved in the direct pathway of glycogen synthesis were
measured to assess if the liver had the capacity to synthesize glycogen. No change in hepatic
GLUT2 protein was detected which is consistent with work in other diabetic models.
Furthermore, this passive transporter is not thought to be the rate limiting step governing hepatic
glucose uptake or glycogen synthesis in healthy subjects 10,47,48. However, work in

59
pancreatectomized diabetic animals has demonstrated increases in GLUT2 protein in the liver
with exercise training, a result not supported in the current study 49. It was suggested that because
these animals had lower circulating glucose levels (one factor known to modulate GLUT2
production) than their untrained controls, which may explain why it was not observed in the
current study 49. GLUT2 mRNA however, has been shown to decrease with training and exhibit a
negative correlation with hepatic glycogen, suggesting that increases in GLUT2 may not be
required for glycogen storage 50.
GK was found to be increased in both diabetic groups, with no modulation with exercise.
STZ induced T1DM has been shown to dramatically reduce GK activity which is subsequently
normalized with insulin treatment 51,52. Furthermore, adenoviral overexpression of GK in rats
with T1DM resulted in a decreased fasting blood glucose, improved glucose clearance during a
tolerance test and increased hepatic glycogen content 21. GK overexpression has also been shown
to increase liver glycogen stores in healthy animals, demonstrative of its control over glycogen
synthesis 17. One potential reason why the increase in GK content was unable to stimulate
glycogen storage is that despite increased protein, activity may still be decreased in T1DM. This
may occur via glucokinase regulating protein (GKRP), which is increased under instances of high
glucose but is unaffected by insulin 53. Under current conditions in which insulin was present but
insufficient to produce normoglycemia, it is conceivable the GKRP might be produced in excess
and subsequently suppress GK activity as a result of hyperglycemia 13,54–56. Park and colleagues
have demonstrated increases in GK content with training in diabetic animals; however, these
animals were not receiving exogenous insulin as were the animals in the current study 49. The
lack of exercise-induced increase could be a result of exercise and insulin working through a
common mechanism with regards to GK expression.
Although direct comparison between GS protein content as measured in the current
experiment and its activity are unfounded, changes in protein content have been linked to changes
in glycogen storage capacity 17,57,58. The current study has reported an increase in GS protein
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content in the livers of DX animals, which, in combination with increased GK content suggest
that the capacity to store glycogen is present in these animals.
The indirect pathway of glycogen synthesis is also known to be perturbed in T1DM, such
that it accounts for a larger proportion of glycogen synthetic precursors than it does in a healthy
state 6–8,22. As flux through the gluconeogenic pathway is largely governed by PEPCK protein
content, data in the current study agrees with this dogma as it is elevated in T1DM, indicative of
increased gluconeogenesis 22,59,60. Insulin is the primary factor controlling PEPCK production,
however, previous work using insulin-treated T1DM has also concluded that insulin treatment is
unable to correct the increase in protein 22,60,61. Inability of the liver to properly decrease
expression of gluconeogenic proteins may be indicative of a resistant state which is unable to be
altered with aerobic exercise.
In addition to dysregulation of glycogenic proteins, it has been shown that patients with
T1DM suffer from an overdriven sympathetic nervous system 62,63. These findings are supported
by previous data from our laboratory using this model of T1DM demonstrating that basal
neuropeptide-Y concentrations are elevated in both exercise and sedentary T1DM rats
(unpublished data). Furthermore, higher levels of glucagon are present within pancreatic islets 5
and, following aerobic exercise training, the glucagon response to an acute bout of exerciseinduced reductions in glycemia is increased relative to pretraining (unpublished data). This is
consistent with the hyperglucagonemia known to contribute to hyperglycemia in T1DM patients
64

. Both sympathetic agents (neuropeptide Y (NPY), epinephrine etc.) and glucagon activate

hepatic glycogen degradation and prevent its synthesis, which may contribute to an overall
hepatic glycogen deficit 10.
Another well-known characteristic of T1DM is hepatic insulin resistance 24,65. If an
insulin signal is not propagating downstream (IRS-AKT-GSK pathway), phosphorylase is likely
to remain active, and consequently, GS will not be effectively activated which will further hinder
glycogen synthesis 25,49,66. To address this, an insulin clamp was done and markers of hepatic
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insulin signaling were measured. Glucose infusion rates required to maintain basal blood glucose
concentrations were higher in both exercised groups compared to sedentary levels; and the
control-exercised animals required the highest rates of glucose infusion, consistent with a) insulin
resistance in T1DM and b) improvements in whole-body insulin sensitivity with exercise training
in both healthy and T1DM subjects 24,67,68.
Interestingly, basal hepatic insulin receptor content was found to be increased in the
T1DM rats of the current study. Insulin receptor content is known to fluctuate based upon
circulating insulin levels, with hyperinsulinemia and hypoinsulinemia decreasing and increasing
receptors, respectively 69,70. T1DM rats in the current study were treated with insulin and
previous work using this model of T1DM found that circulating levels were equivalent to that of
control animals, so it is unclear why IR content is elevated 41. It is possible that differences exist
between endogenous rat insulin and the human insulin that the T1DM animals are treated with in
their ability to bind and/or activate the IR. The importance of the insulin receptor in hepatic
insulin resistance has been demonstrated by liver insulin receptor knockout (LIRKO) mice which
demonstrate impairments in glucose clearance and suppression of hepatic glucose production, as
well as insulin signaling defects with regards to activation of its substrates IRS 1 and 2 71.
Interestingly, upregulation of insulin receptors has also been shown to improve insulin sensitivity
and glucose clearance in cultured human hepatocytes 72. This appears to contradict the widely
accepted notion that T1DM suffer from hepatic insulin resistance 24. Reasons for this discrepancy
are unclear, however, the etiology of hepatic insulin resistance is also illusive in T1DM so it is
possible that defects more distal in the signaling pathway are the root cause and receptors are
being upregulated in an attempt to compensate.
To assess insulin signal transduction, insulin induced inhibition of GSK-3β, a key
effector upon GS, was measured following the hyperinsulinemic clamp. No change in GSK-3β
phosphorylation was detected in T1DM rats in comparison to non-T1DM, suggesting that the
insulin signaling pathway is not perturbed in T1DM. Although mechanistic studies in T1DM are
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lacking, recent work using another model of hepatic insulin resistance, in which hepatic NFκB is
hyperactive, showed decreases in GSK-3β phosphorylation following insulin stimulation 25. That
same model found decreased hepatic glycogen storage as well as impaired suppression of hepatic
glucose production, two known features of T1DM 24,25. While this appears to suggest normal
hepatic sensitivity in the current study, it is important to note that modulation of GSK is not the
only way insulin modulates glycogen synthesis. Many other protein kinases including adenosine
monophosphate-dependent protein kinase (AMPK), Protein Kinase A, AKT (also known as
protein kinase B), and calmodulin induced protein kinase (CamK) among others are able to
phosphorylate GS and are also modulated by insulin10,15,73,74. GSK-3β phosphorylates residues
known to be important to GS activity yet can only do so when other residues have already be
phosphorylated (referred to as hierarchal phosphorylation) by other proteins. Alterations in any
of the above mentioned factors could, therefore, also affect GSK-3β’s ability to modulate GS
activity 10,73.
As GS is most active in its unphosphorylated state, defects in its dephosphorylation will
also strongly modulate its ability to synthesize glycogen. Protein phosphatase 1 (PP1), the
primary phosphatase of hepatic GS, is also altered in T1DM 75. PP1 activity towards GS was also
shown to be dependent on the degree of insulin deficiency 75. More recent works have
demonstrated that a subunit of PP1, GL, that targets PP1 to a glycogen granule, was absent in
T1DM 76. This, however, was also corrected with insulin therapy 76. As previously mentioned,
animals in the current study were not given sufficient insulin to achieve normoglycemia so it is
unclear whether or not PP1 and/or GL deficiencies play a role in the glycogen deficit.
Insulin stimulated glycogen synthesis has also been shown to stem from AKT-mediated
inactivation of GP. GSK-3β is a downstream target of AKT; however, constitutively active AKT
mutants stimulate glycogen synthesis in cultured hepatocytes; even in the presence of the GSK-3β
inhibitor SB-216763 66,77. Furthermore, cells with overactive AKT had decreased GP activity and
greater levels of glycogen synthesis than in GSK-3β inhibited cells alone 66,77. It should be noted
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that GSK-3β is still an important regulator of GS activity, but active GS alone does not appear to
be sufficient to drive glycogen synthesis 66. Although the mechanism by which this occurs is not
understood, it suggests that glycogen accumulation can be hindered despite normal GSK-3β
phosphorylation in response to insulin.
Differences between the current study and other published works may also stem from
measurement technique. Assessment of insulin-induced suppression of hepatic glucose
production gives a measure of hepatic response to insulin, but does not decipher the mechanistic
details with respect to the known direct and indirect effects of insulin on the liver 78. The direct
effects of insulin are the alteration of hepatic glycogenolysis (discussed above) and
gluconeogenesis, which is largely mediated through an AKT-mediated inhibition of PEPCK
transcription 78. The indirect effects of insulin include its manipulation of circulating levels of
glucagon, non-esterified fatty acids (due to decreased adipose and skeletal muscle lipolysis),
gluconeogenic precursor glycerol, as well as neural signals stemming from the hypothalamus 78.
It has also been suggested that the indirect effects of insulin are greater effectors on hepatic
glucose production in rodents than its direct effects, making comparisons between the current
study and other existing works quite confounded 79.
In addition to insulin signaling, post-clamp glycogen was measured in both the liver and
soleus muscle to assess where glucose is being stored during an insulin stimulus. Soleus
glycogen was significantly increased in exercise-trained groups, consistent with improvements in
peripheral insulin sensitivity following training. All groups had equivalent liver glycogen levels
following the clamp, which is consistent with what is known to occur following an overnight fast
9

. Furthermore, euglycemic clamps do not stimulate glucose uptake via the GLUT2 transporter

and, subsequently, do not stimulate significant hepatic glycogen storage 9,80,81. This is an
interesting finding as the control and diabetic groups were clamped at different blood glucose
concentrations. Control and diabetic animals were clamped at 5mM and 15mM blood glucoses
respectively, in an attempt to assess insulin sensitivity at their resting blood glucose
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concentration. However, the T1DM animals were clamped in what is typically considered a
hyperglycemic, not a euglycemic, range. Contradictory to the current study, previous works
using clamps in this range have shown increases in liver glycogen following a hyperglycemic
clamp in animals with T1DM 82. Differences in the model of T1DM (STZ vs pancreatectomy), as
well as disease duration, may account for this discrepancy; however, another possibility does
exist. As has been posited for other conditions such as baroreflex sensitivity in hypertension, it
is possible that, following sufficient duration of T1DM, a “resetting” of the homeostatic resting
blood glucose may occur 83. If, for example, the liver in these diabetic animals perceives 15mM
as a new normoglycemia, it is unlikely that glucose would be taken up during the insulin clamp
and glycogen would be stored. This would account for lack of storage in the present study and
also lend support to tighter regulation of resting blood glucose being beneficial in T1DM 1.
Future works examining intracellular glucose and glucose-metabolite levels in these animals
would help elucidate why hyperglycemia is unable to stimulate hepatic glycogen synthesis.
Furthermore, use of this model in conjunction with more intensive insulin treatment and
normoglycemia will help to determine if this is the case.

2.5

Conclusion
In conclusion, the current study demonstrates that 10 weeks of aerobic exercise training is

not able to improve the deficit in hepatic glycogen content in rats with T1DM. This was also
associated with a lack of training-derived improvements in GLUT2, GK and PEPCK protein
contents, and increases in GS protein in exercised T1DM animals. These data indicates that the
capacity to synthesize glycogen is not hindered in these animals and may suggest that metabolic
signaling deficits are somehow hindering synthesis. However, GSK-3β inactivation following an
insulin clamp was unchanged with either exercise training or T1DM, suggesting that an insulin
signal is capable of reaching the key effectors on GS activation. Of course the possibility remains
that other protein kinases capable of phosphorylating GS may be deregulated in T1DM, and
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provides avenues for future investigation. Additionally, other insulin functions, such as
modulation of GS phosphatases as well as GP activity and gluconeogenic flux may all play a role
in hindering glycogen synthesis. Finally, it is possible that a “resetting” of blood glucose
homeostasis is hindering glucose uptake such that glycogenic substrates are not present to drive
glucose metabolism towards storage. All of these results indicate the complexity of glycogen
storage and, despite the known benefits of exercise upon T1DM-related complications, suggests
that exercise training is not an effective way to improve hepatic glycogen storage in T1DM rats.
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Appendix A
A1, Streptozotocin Induction
REVISION DATE: 13/06/2012
PURPOSE:
To induce Type I diabetes in rats
MATERIALS:
Gloves
Lab Coat
Streptozotocin (STZ)
5X Stock Citric Acid/Citrate Buffer
Anhydrous Citric Acid
Sodium Citrate Dihydrate
MilliQ Deionized Water
13M HCl
3 Falcon Tube
Sterile Filter
EQUIPMENT:
Biological Safety Cabinet
Weigh Scale
pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
ii. 23.8g Sodium Citrate Dihydrate (Sigma)
Mix into iii. 175mL of MilliQ water
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml mark (pH
will move slightly). If satisfied with the pH, adjust volume in a 250 ml graduated cylinder
and filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate amounts
of STZ to be prepared.
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of distilled
water filtered through a 0.2µm syringe filter. Check the pH. This gives you a working
concentration of 153 mM
2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is reached.
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe filter
as before). If pH is below 4.5, restart.
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4. Weigh out an appropriate amount of STZ for the number of animals (see calculations below)
that will be injected in a 15 minute time frame.

Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g (avg.
weight of rats to be injected), you will require a minimum of 40mg.
20mg/kg X 0.2kg = 4mg per animal
The amount of STZ weighed out should be more than the minimum as some solution will be
lost in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g)
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume). Shake to
dissolve powder (approx. 1min). Sterile filter using a 0.2µm syringe filter.
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution
4mg ÷ 16mg/mL solution = 0.25mL
6. STZ is time dependent and must be used within 15 minutes
Injecting and Follow-Up of the Animals
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of 20mg/mL (in
this example, 0.25mL). Do not use anymore STZ solution more than 15 minutes after it has
been dissolved in the sodium citrate buffer.
2. Dispose of any container having come into contact with the STZ (in either powder or
dissolved form) into a biohazardous waste receptacle. Dispose of needles into a sharps
container.
3. Return injected rats to their cage. Record the date of STZ injection and add a biohazard label
to the cage (leave biohazard label on cage for at least 3 days following the last injection).
4. Repeat this procedure the following day.
5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol Diabetes should be achieved after 5-8 injections (i.p. 20mg/kg).
Reference:
Low dose STZ induction protocol. Animal Models of Diabetic Complications Consortium
AMDCC Protocols.2003
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A2, Insulin Pellet Implant
REVISION DATE: 13/06/2012
MATERIALS:
LinShin LinPlant Insulin Pellet
Rat anesthetic - Isoflurane
Ampicillin
Sterile water
1ml syringe with 25 g needle
10% providone-iodine solution
gauze (or swab)
Tissue forceps
Scalpel handle and blades (or scissors)
Silk suture
Needle drivers
EQUIPMENT:
IsofluoraneAnaesthetic Machine
Hair clippers
Heat lamp
Special Safety:
Must don lab coat and gloves before handling rodents. Any bite or scratch that breaks the skin
must be thoroughly scrubbed with soap and water (report to Occupational Health and Safety).
PROCEDURE:
Pellet implantation (for a rat):
1. Anesthetize the animal using the isofluorane machine by placing it in the induction chamber.
Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the stopcock valve so gas
reaches the chamber. Keep in chamber until the animal is unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to 3% to
maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin, followed by 70%
ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the puncture
site to a depth of at least 2 cm.
7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse with saline
and insert into the subcutaneous region.
8. Use 1 pellet for the first 350g of body weight.
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9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providone-iodine
solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.

Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by applying
10% providone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the location of
the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut away using
scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.
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A3, Glycogen
REVISION DATE: 13/06/2012
MATERIALS:
Tissue samples
Fume hood
3 x 100mm glass test tubes
Potassium hydroxide (KOH) pellets
Sodium sulfate (Na2SO4)
95% ethanol
Glycogen powder
Phenol crystals
96-98 % Sulfuric Acid (H2S04)
490nm spectrophotometer
Standard Curve:
Prepare standard curve with stock glycogen solution (1mg/mL).
Standard
1
2
3
4
5
6
7

[Glycogen] (mg/ml)
0.000
0.005
0.010
0.050
0.100
0.200
0.300
0.500
1.000

Volume (μl)
0
5
10
50
100
200
300
500
1000

Water (μl)
1000
995
990
950
900
800
700
500
0

Colour Reaction:
Add 1 ml of 5 % phenol.
Rapidly add 5 ml of 96-98 % H2S04.
Let samples stand for 10 min.
Vortex and place in water bath (25 to 30C) for 10 to 20 minutes.
Read tubes at 490 nm.
Procedure:
1.

Cut and weigh approximately 20mg of tissue samples and place in glass test tube.

2.

Saturate 30% KOH stock solution with sodium sulfate (Na2SO4)
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3.

Add 0.5 ml of 30 % KOH saturated with Na2S04. Make sure that tissue is completely
submerged.

4.

Put caps on tubes and immerse in boiling water bath until homogenous solution is
obtained (30 minutes).

4.

Place tubes on ice.

5.

Precipitate glycogen with 1mL of 95 % ethanol for 30 minutes (on ice).

6.

Spin tubes at 840 x g (3 000 rpm on Sorval) for 20 to 30 minutes.

7.

Remove supernatants and immediately dissolve precipitates in 3mL ddH2O. Do not allow
precipitated to dry.

8.

Pipette 1 ml glycogen solution into 3 separate glass test tubes (3 x 100mm).
- 3 separate tubes of glycogen solution are necessary for analysis in triplicates.

9.

Add 1 ml of 5 % phenol.

10.

Rapidly add 5 ml of 96-98 % H2S04.

11.

Let samples stand for 10 min.

12.

Vortex and place in water bath (25 to 30C) for 10 to 20 minutes.

13.

Read tubes at 490 nm.

14.

Calculate glycogen content by:
g of glycogen / 100g tissue = A490 x V x 10-4
k
v W

where, V = total volume of glycogen solution; v = volume of aliquot used in colour
reaction; A490 = absorbance at 490 mn; W = weight of tissue samples in grams; k = slope
of standard curve; units = 1 per microgram glycogen.
SOLUTIONS:
Glycogen Stock Solution
(1mg/mL)
100mL
ddH2O
100mg
Glycogen powder
30% Potassium Hydroxide Stock Solution
300g
Potassium Hydroxide Pellets
(KOH)
1L
ddH2O
Reaction is exothermic; therefore, it might be
necessary to put on ice.
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SPEC. PROCEDURE:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Turn on ~20minutes before needed (TRANS)
Set desired λ& insert appropriate filter
Insert a blank tube (dH2O)
With spec. on “TRANS”, set to 0.000 using “zero” button & while pressing “zero set”
Release “zero set”, but adjust value to 100.00 with spec set to “TRANS” using “100%
T/OA” adjustments
Set spec from “TRANS” to “ABS” using LHS button
Check that “ABS” reading is 0.00; if not adjust with “100%T/OA”
Check that a true a zero reading has been reached by reading the abs values of 2 other
blank tubes
Read 3 reagent tubes (blank) and record zero on the middle value using “100%T/OA”
Read all standard samples

Reference:
Lo, S.L., Russell, J.C., and Taylor, A.W. (1970) J Appl. Physiol, 28(2), 234-6.
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A4, Western Blot
SEPARATING GEL (makes 4 10% gels)
 Remove samples and allow to thaw on ice.
 Clean mini-gel plates with 70% ethanol before use.
 Assemble gel cassettes and check for leaks.
 Prepare separating gel in a small beaker with continuous stirring.
o Prepare a 10% ammonium persulfate (APS) solution; prepare fresh each time.
Measure out 50mg of APS into a 1.5 mL Eppendorf tube and add 450 μL of
double distilled water (ddH2O).
o Add 15.992mL of ddH2O
o Add 13.333mL of Acrylamide solution1; begin to stir
o Add 10mL of Separating gel buffer2
o Add 400μL sodium 10% SDS3
o Let stir for a minimum of 10 min
o Add 250μL of 10% APS solution and 25μL of tetramethylethylenediamine
(TEMED) simultaneously and let stir for about 20 seconds.
 Quickly pour the gel into each cassette with a Pasteur pipet up to about 1.5cm from the
top of the short plate.
 Try to remove most bubbles by tipping the apparatus and/or soaking them up with filter
paper.
 Immediately overlay each gel with about 1cm of water-saturated butanol.
 Allow gel to polymerize 30-60 min
 Continue preparing samples:
o Vortex samples and pipet appropriate volumes into a set of labeled tubes
o Add an equal volume of 2X Lammeli SDS-PAGE sample buffer4 to each tube
(each tube should now be a 1:1 mixture of homogenized sample to sample
buffer)
o Mix samples thoroughly, and centrifuge to pull all contents down if necessary.
STACKING GEL (makes 4 4% gels)
 Clean lane combs with 70% ethanol.
 Prepare the 4% stacking gel in small beaker with continuous stirring
o Add 12.2 mL of ddH2O
o Add 2.6 mL of Acrylamide solution; begin to stir
o Add 5 mL of Stacking gel buffer5
o Add 200 μL of 10% SDS
o Let stir for a minimum of 10 min
 While stirring and once separating gel has polymerized, dump butanol overlay down the
sink
 Dry exposed glass plates (above separating gel) with filter paper.
 After 10 min of stirring, add 125μL of 10% APS and 25μL of TEMED simultaneously
and let stir for about 20 seconds.
 Quickly pour the gel into each cassette with a Pasteur pipet up to the top of the short
plate.
 Carefully place lane combs in between the two plates, making sure no bubbles are
trapped beneath it.
 Allow gel to polymerize for 30-60 min
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Continue preparing samples:
o Bring water in a metal container to 75-80°C and place samples in water. Heating
times vary (approximately 3-10min)
o Remove from hot water and let cool at room temperature before loading onto gel.
o Mix samples again by vortexing and centrifuge to pull down contents if
necessary.
o Prepare 1X running buffer6 (25mM Tris, 192 mM glycine, 0.1% SDS) from 10X
running buffer and refrigerate. Approximately 1L is needed per electrophoresis
unit.

STACKING GEL
 Once stacking gel has polymerized, carefully remove gel cassettes from apparatus and
transfer to electrophoresis electrode modules.
o Each BioRad Mini-Gel Protean Tetra Cell electrophoresis unit holds one
“electrode” module and one “companion” module, and each module holds two
gels. If running only two gels, you must use the “electrodue” module.
o Make sure each cassette is as far down as possible on the modules.
o Make sure the short plate faces the inside of the module.
o For electrophoresis to work, you need a closed-in compartment on the inside. If
running an odd number of gels, you can place an unused cassette, but the
“spacer” plate facing the inside, opposite to the lone gel in order to seal off the
inside compartment.
o **Make sure you can identify your gels
 Remove the lane combs and fill each well about halfway with 1X running buffer with a
Pasteur pipet.
 Load the correct amount of each sample into each corresponding well using a
micropipette
o Based on 1:1 sample to sample buffer mixture, each well will contain a different
volume of sample to equalize protein amounts.
o Load 5 μL of chemiluminescent ladder (BioRad Precision Plus Protein Standards
Kaleidoscope #161-0375 or #161-0324)
 Fill the inside compartment of the electrode modules with 1X running buffer to a level
above the short plate to cover the wells.
 Fill the rest of the tank (outside the gel cassettes) with cold 1X running buffer to the same
level.
ELECTROPHORESIS
 Place electrophoresis unit into a second larger container and cover it. Ensure the
electrodes match the lid: ie red to red and black to black.
 Fill container with ice
 Connect lid electrodes to the power unit.
 Generally, run at a low voltage (50-70) until the dye has passed through the stacking gel.
Then turn it up to 110-125 for the remainder of the run.
 As this is taking place, prepare the transfer buffer7 (25 mM Tris, 192 mM glycine, 0.1%
SDS, 20% methanol), and cut filter paper and nitrocellulose.
 Put a layer (arbitrary volume) of cold transfer buffer into a baking dish and soak the
nitrocellulose, filter paper and brillo pads
TRANSFER
 Once electrophoresis is complete, unplug unit and remove lid.
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Using the “wedge” piece, separate the short and spacer plates to reveal the gel. Slice off
the stacking gel.
Dislodge the gel from the spacer plate and assemble the “sandwich” in the transfer
apparatus:
o Place the “positive” end (white) of the sandwich frame on the bottom.
o Stack the individual components as follows: 1 brillo pad, 2 filter papers, 1
nitrocellulose piece, gel, 3 filter papers, 1 nitrocellulose piece, gel, 2 filter papers,
1 brillo. The “negative” end (black) of the sandwich frame is on top, and secures
the sandwich.

Apply pressure on the sandwich before closing to try to remove bubbles between the gel
and nitrocellulose.
Place the closed sandwich in the transfer electrode module and place this in the transfer
tank. ****Remember to orient it correctly in the module.
Place an ice pack in the tank and fill it with cold transfer buffer.
Place the transfer unit into a second larger container and cover the unit with the lid.
o Ensure electrodes match on the module and lid (ie. red to red and black to black)
Fill container with ice.
Connect the lid electrodes to the power unit.
Generally, transfer is 70V for 90min
While transfer is taking place, prepare 1X Tween TBS8 (TTBS; 10mM Tris pH 7.5, 100
mM NaCl, 0.1% Tween-20) from 10X TBS, and blocking solution 9a,b.
o Prepare 2L of TTBS for 4 blots
o Select small, shallow containers to incubate blots
o Prepare 25-30 mL of blocking solution per container.

BLOCKING
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Once transfer is complete, unplug from the power unit and remove the lid from the
transfer tank.
Remove each piece of nitrocellulose and place in the prepared blocking containers with
blocking solution.
Place only two pieces of nitrocellulose “blots” per container and ensure they are back-toback.
Allow to incubate for 1 hr at room temperature with gentle shaking (~40 rpm).
Prepare the primary antibody solution10,11
When blocking is complete, wash blots once with TTBS
o Dump blocking solution down the sink and replace with TTBS.
o Allow to wash for 5 min at room temperature with vigorous shaking (~90 rpm).

PRIMARY ANTIBODY
 Dump TTBS down the sink and replace with prepared antibody solution.
 Allow blots to incubate overnight (12-16 hours) at 4°C with gentle shaking (~60 rpm).
 Before primary incubation is stopped, prepare the secondary antibody solution12 in 50mL
falcon tubes.
 Once primary antibody incubation is done, remove any unbound primary antibody with
three successive washes and rinse in TTBS (10 min with vigorous shaking ~90rpm).

SECONDARY ANTIBODY
 Dump TTBS down the sink and replace with the previously prepared secondary antibody
solution12.
 Allow blots to incubate for 60 min at room temperature with gentle shaking (~40 rpm).
 Prepare 1X Tris buffered saline13 from 10X TBS
o Prepare 100mL of TBS for 4 blots (2 containers).
 Once secondary antibody incubation is done, remove any unbound secondary with three
successive washes and rinses in TTBS (10 min with vigorous shaking ~90 rpm).
 After last TTBS rinse, perform one final rinse with TBS13 and leave blots in an
unspecified volume of TBS.
CHEMILUMINESCENT
 Turn on the BioRad Chemidoc XRS System, open the Quantitiy One 1-D analysis
program
o Select band analysis guide from the toolbar, and a pop-up with a list of items
should appear on the top right of the screen
o Click on “select scanner” and select “Chemidoc XRS”
o In the control window, click “Live/Focus” and press “Epi White” on the
chemidoc system.
 Clean the inside surface of the Chemidoc with 70% ethanol
 Prepare BioRad chemiluminescence substrate in a 1.5mL Eppendorf tube
o Pipet 500 μL of Luminol solution and 500 μL of peroxide solution in the
Eppendorf and mix.
 Place blots on transparency and pipet chemiluminescence solution over blot. Close
transparency.
 Place blot in chemidoc drawer and align it to the center
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In the control window, check “highlight saturated pixels” box near the bottom, and click
the “Open Iris” button repeatedly.
o Saturated pixels will be displayed red, and there should be a “pulsating” ellipse
of red pixels in the center of the display.
o Continue pressing this button until the size of the ellipse is no longer noticeably
increasing.
Close the chemidoc door and press “Epi White” again to turn off the light.
Click “freeze” in quantity one and click “Live Acquire”
A pop-up appears and you can decide exposure parameters
Allow the camera to detect chemiluminescence for the total exposure time.
o Choose an image in which your bands of interest are just on the verge of
saturation.
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Appendix B
B1, Ethics
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